



EAU26 | LONDON, GB

13-16 March 2026

Cutting-edge Science at Europe's largest Urology Congress

Rules and regulations late-breaking abstract submission

Deadline:

25 January 2026 at 23:59 Central European Time (CET)

- To avoid technical issues, submit well before the deadline.
- Use Google Chrome (latest version) for submitting your abstract.
- Edit and withdrawal: Until the deadline, authors can make changes or withdraw abstracts via the submission system. Changes after the deadline is not possible. Withdrawal after the deadline requires an email to abstracts@congressconsultants.com

Submission timeline:

- Deadline submission: **25 January 2026, 23:59 CET** via the EAU26 abstract submission website. Select presentation type: Late-breaker
- Anonymous review and selection by the Scientific Congress Office
- Outcome communicated to submitter: **13 February 2026**

Definition and criteria

Late-breaking abstracts are intended for high-impact research that was not complete or available by the regular submission deadline, 1 November, 23:59 CET. Submissions must present novel, time-sensitive data of major scientific importance — such as results from pivotal clinical trials or breakthrough studies — that could not have been submitted or presented earlier. Late-breaking abstracts are subject to stricter selection criteria and must include robust, final data at the time of submission. Preliminary or incomplete data will not be accepted.

At the end of the submission, authors are required to provide a rationale in the question section, explaining why they believe their abstract meets the late-breaking criteria.

Before entering the abstract submission system you are requested to carefully read the following rules.

Additional implications (on top of/overruling the standard submission rules and regulations):

- You can only submit the abstract once to the EAU26 late-breaker submission – double submitted abstracts will not be reviewed
- Very limited places are available for late-breaking abstracts in the programme, therefore the selection will be done very critically

Rules & regulations of a submitting a late-breaker abstracts

- Abstract(s) may not have been published before the start of the Annual EAU congress in London on 13 March 2026. **No encore abstracts are accepted.**
- All abstracts must be submitted in **English**.
- All sources of financial support (including government grants) or companies which handled the data must be filled out in the designated question during the submission procedure (and not in the abstract text). All grant



EAU26 | LONDON, GB

13-16 March 2026

Cutting-edge Science at Europe's largest Urology Congress

funding agencies and/or company abbreviations should be spelled out. This information will be published with the full body abstract, wherever it is reproduced on the EAU's publications, channels or online.

- Accepted abstracts will be published as submitted.
- One of the authors or someone assigned by the authors should defend the abstract physically in London during the session and therefore needs an on-site registration. If no one can defend the abstracts physically during the congress, the abstract will be removed from the session and no certificate of presentation will be available.

Copyright

- Copyright of the accepted abstract is assigned to the European Association of Urology and any conflicts with any other scientific association will be the sole responsibility of the author(s).
- All accepted abstracts, including figures and tables, are property of EAU and are protected by copyright.
- By submitting an abstract you agree (also on behalf of co-authors) to the terms of use and conditions as stated above. Please note that transfer of copyright applies to all material submitted (such as videos, slide/audio presentations, live-streams, webcasts, poster PDFs and all other materials). Moreover, the submission of an abstract affirms that all authors named in the abstract have agreed to its submission for presentation at the Annual EAU congress.
- Requests for re-use of material can be done by sending an email to abstracts@congressconsultants.com (please include the abstract code)

Publication

By submitting an abstract you agree (also on behalf of (co-)authors) that the accepted abstract as well as related materials such as videos, slide/audio presentations, live-streams, webcasts, poster PDFs and any other materials are published on EAU publications and media channels.

Publication in European Urology

For a selected number of high-impact late-breaking abstracts, the EAU and European Urology are pleased to offer the possibility of simultaneous publication, which enables authors to present their research at the annual EAU meeting concomitant to the publication online of their full article. This embargoed publication in our flagship journal includes fast-track submission with expedite review completed in 72 hours and coordinated release of the manuscript on the day of presentation at the EAU Annual Congress.

Authors who wish to be considered for this opportunity should indicate so by contacting the abstract selection committee via h.kiss@uroweb.org. In that case, your full manuscript should be close to final form by the late-breaking abstract submission deadline. Candidate abstracts will be reviewed by the European Urology editorial team, and authors of abstracts deemed eligible will be invited to submit a full manuscript by the journal editor. As such, by letting us know, you give permission to share your abstract with the European Urology editorial team.

Please note that all submissions will undergo the standard rigorous peer-review process, and acceptance cannot be guaranteed. An invitation to submit reflects the journal's interest in your work but does not imply automatic publication



EAU26 | LONDON, GB

13-16 March 2026

Cutting-edge Science at Europe's largest Urology Congress

Content related instructions

Ethical approval and human experimentation

In clinical studies, the authors must state that an Ethical Committee approval has been obtained.

Please note that the statement should clearly indicate whether the approval was obtained or not, accompanied by a brief explanation of the reason in case of a disapproval. This information is necessary for the proper processing of the review. Any human experimentation conducted with respect to the submitted abstract(s), should have been conducted according to the protocol approved by the institutional or local committee on ethics in human investigation; or, if no such committee exists, the works should have been conducted in accordance with the principles of the Declaration of Helsinki of World Medical Association. Council may enquire further into ethical aspects when evaluating the abstract(s).

Case reports

Only high quality case reports accompanied by a systematic literature review, which is based on a clearly defined protocol, are allowed. Other case reports are not eligible for submission and/or subject to desk reject.

Systematic reviews

Systematic reviews (with or without meta-analysis) can be submitted only when they meet the following standards:

- The clinical question studied is highly relevant to current practice and/or practice changing
- The clinical question was clearly defined using a standard PICO format
- A comprehensive systematic literature search was carried out
- An assessment of the risk of bias was made
- Key findings are clearly described including clinical practice relevance

Trial in progress

Trials in Progress abstracts offer researchers a platform to present ongoing trials, promote collaboration, and discuss correlatives and innovative trial designs. It is expected that abstracts submitted as Trial in progress are ongoing trials that have not reached any protocol-specified endpoints for analysis.

Trial in Progress abstracts should contain the following two sections and should not have data analysis available before the submission deadline.

- **Introduction and objectives**
Provide the scientific background and rationale of the trial, highlighting correlative studies of interest.
- **Materials and methods**
Detail the trial design and statistical methods, emphasizing any innovative aspects.

Outline the planned interventions and specify major eligibility criteria.

Report current enrolment without disclosing protocol-specified results.
State clinical trial registry number.

Topic

A topic has to be selected from the drop-down menu. For the review of the abstract, it is of vital importance that the correct (sub)topic, clinical step(s) and management tool(s) are selected.



EAU26 | LONDON, GB

13-16 March 2026

Cutting-edge Science at Europe's largest Urology Congress

Authors and Affiliations

- A maximum of 24 authors per abstract is allowed.
- Each author should have contributed substantially to the represented work in terms of conceptual design or analysis, writing of the article and final approval of the article in order to take public responsibility for the content.
- An abstract presenter is limited to 5 abstract presentations.
- Please make sure to write the name of the Organisation/Institution, Department, City and Country in English (one institution per author).
- If co-authors are from the same institution, the programme will automatically copy all information into the next boxes, so you do not have to type all information again. If co-authors are not from the same institution you can edit any box as your wish.
- There is only the possibility to enter one first author, one presenting author and one last author.
- Do type family name and full first name of all authors. Do NOT type titles, degrees and institutional affiliations. Carefully check the correct spelling of all names as this will be the way that names will be published.

Formatting guidelines

Abstract Size

The size of the abstract is limited to 3,000 characters (this includes title, body of abstract, spaces, tables and pictures/graphics). The submission programme will automatically calculate the size of your abstract and will not allow submissions that do not fit in the size requirements. A picture/graphic counts for 500 characters.

Detailed instructions of formatting is available on the right side of the submission site.

Proof reading

After you have inserted all data for your abstract submission a preview will show on your screen. Please verify that your abstract submission is correct and read this preview carefully (including author information). Keep a print for your own records.

It is the responsibility of the submitting author to ensure the abstract is in perfect order with no errors in spelling or grammar, as revisions will not be accepted. Abstracts will not be corrected.

Late-breaking abstract review process

All abstracts are subject to peer review and are expected to meet the standards of academic/scientific excellence. Submissions will be reviewed by the member of Scientific Congress Office whose identities will remain anonymous to the authors. Reviewers will give scores from 1 to 5 points, taking into consideration the following criteria: High scientific significance, originality, priority, quality of research methodology and data. Review and session composition will take place in February 2026. The outcome of the abstract selection is available online through the abstract submission website around 13 February 2026. You will receive a notification by email.

The Scientific Congress Office reserves the right to obtain your raw data for statistical evaluation.

For any questions, please send an email to abstracts@congressconsultants.com